Immunotherapy of Cancer

An Innovative Treatment Comes of Age

  • Yoshiyuki Yamaguchi

Table of contents

  1. Front Matter
    Pages i-ix
  2. Overview, History, Classification

    1. Front Matter
      Pages 1-1
    2. Yoshiyuki Yamaguchi
      Pages 3-17
  3. BRMs and Crude Agents

    1. Front Matter
      Pages 19-19
    2. Junichi Sakamoto, Michitaka Honda, Toru Aoyama
      Pages 21-35
    3. Yasuyuki Sugiyama
      Pages 37-50
    4. BCG
      Yoichi Mizutani
      Pages 51-59
  4. Adoptive Cell Therapy

    1. Front Matter
      Pages 61-61
    2. Atsushi Aruga
      Pages 63-73
    3. Shinichiro Motohashi
      Pages 75-86
    4. Satoshi Kokura
      Pages 87-98
    5. Hirokazu Matsushita, Kazuhiro Kakimi
      Pages 99-119
    6. Hiroaki Ikeda
      Pages 121-132
  5. Vaccine Therapy

    1. Front Matter
      Pages 133-133
    2. Koji Kono
      Pages 135-142
    3. Masanori Noguchi
      Pages 143-158
    4. Yoshihiro Oka, Akihiro Tsuboi, Hiroko Nakajima, Fumihiro Fujiki, Sumiyuki Nishida, Soyoko Morimoto et al.
      Pages 159-185
    5. Shinichi Kageyama
      Pages 187-196
    6. Masato Okamoto
      Pages 197-220
  6. Immunoadjuvants

    1. Front Matter
      Pages 221-221
    2. Masahiro Katsuda, Hiroki Yamaue
      Pages 223-233
    3. Burcu Temizoz, Etsushi Kuroda, Kouji Kobiyama, Taiki Aoshi, Ken J. Ishii
      Pages 247-260
  7. Immunocheckpoints

    1. Front Matter
      Pages 261-261
    2. Takuto Tokudome
      Pages 263-282
    3. Yoshimasa Tanaka, Craig T. Morita, Haruki Okamura
      Pages 283-294
  8. Regulation of Immunosuppression

    1. Front Matter
      Pages 307-307
    2. Hideya Onishi, Takashi Morisaki, Mitsuo Katano
      Pages 309-322
    3. Masahiko Shibata, Kenji Gonda, Seiichi Takenoshita
      Pages 323-334
  9. Immune-Related Response Criteria and Guidance for Clinical Trials

    1. Front Matter
      Pages 335-335
  10. Personalized Immunotherapy

    1. Front Matter
      Pages 347-347
    2. Yutaka Kawakami, Boryana Popivanova, Sunthamala Nuchsupha, Taeko Hayakawa, Kenta Nakamura, Haruna Nagumo et al.
      Pages 349-358

About this book


This timely book, published just as cancer immunotherapy comes of age, summarizes the rationale, present status, and future perspective for cancer immunotherapy. Included are explanations of the constitution of the immune system and immunocheckpoints, the mechanism of antigen presentation and recognition, valuable modalities, clinical trials and guidance, personalization, and biomarkers, all of which are essential for understanding the success of cancer immunotherapy. This innovative therapy has been investigated worldwide as the fourth line of cancer treatment after the standard treatments of surgery, chemotherapy, and radiotherapy. The progress in fundamental understanding of tumor immunology and the recent advances in clinical trials have opened new avenues with a cancer vaccine in 2010 and immunocheckpoint modulation in 2011, with their approval already granted in the United States. Today, there are no doubts, even among experts in cancer chemotherapy and radiotherapy, that the immune system plays a vital role in tumor eradication. Following American approval, many clinical trials of cancer immunotherapy are being conducted.

 With this book the reader will readily understand the paradigm shift in cancer treatment and will realize the importance of cancer immunotherapy. The great value of immunotherapy will be obvious, not only for tumor shrinkage but for prolonging patient survival.


biomarkers cancer vaccine immune checkpoints tumor immunology cancer immunotherapy

Editors and affiliations

  • Yoshiyuki Yamaguchi
    • 1
  1. 1.Department of Clinical OncologyKawasaki Medical SchoolOkayamaJapan

Bibliographic information